|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
EP2365001A3
(en)
|
2003-05-01 |
2012-03-28 |
Imclone LLC |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
HUE038955T2
(hu)
*
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
BRPI0607315B1
(pt)
|
2005-02-07 |
2022-05-17 |
Roche Glycart Ag |
Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
|
|
CA2678008C
(en)
|
2005-06-17 |
2013-07-30 |
Imclone Systems Incorporated |
Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
|
|
AU2006290433B2
(en)
*
|
2005-08-26 |
2012-06-07 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
AU2007212447B2
(en)
|
2006-02-03 |
2013-02-21 |
Imclone Llc |
IGF-IR antagonists as adjuvants for treatment of prostate cancer
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
NZ581468A
(en)
|
2007-06-25 |
2012-09-28 |
Esbatech Alcon Biomed Res Unit |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
|
US20110243931A1
(en)
*
|
2007-09-02 |
2011-10-06 |
Thomas Friess |
Combination therapy with type i and type ii anti-cd20 antibodies
|
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
|
KR20100102172A
(ko)
*
|
2007-12-21 |
2010-09-20 |
제넨테크, 인크. |
리툭시마브-난치성 류마티스성 관절염 환자의 요법
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
MX2010010027A
(es)
*
|
2008-03-13 |
2011-05-02 |
Biotest Ag |
Agente para tratar enfermedad.
|
|
EP2262838B1
(en)
*
|
2008-03-13 |
2016-04-13 |
Biotest AG |
Agent for treating disease
|
|
RU2539110C2
(ru)
*
|
2008-03-13 |
2015-01-10 |
Биотест Аг |
Способ лечения аутоиммунного заболевания (варианты)
|
|
BRPI0909227B8
(pt)
*
|
2008-03-25 |
2021-05-25 |
Roche Glycart Ag |
uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
|
|
EP2282769A4
(en)
*
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
EP2297209A4
(en)
*
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR20110016959A
(ko)
*
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8822645B2
(en)
*
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
RU2531548C2
(ru)
*
|
2008-09-29 |
2014-10-20 |
Биотест Аг |
Композиция для лечения заболевания
|
|
AR075982A1
(es)
*
|
2009-03-31 |
2011-05-11 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
CN102378768A
(zh)
|
2009-04-07 |
2012-03-14 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-3/抗-c-Met抗体
|
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
|
CN102361884A
(zh)
|
2009-04-07 |
2012-02-22 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-2/抗-c-Met抗体
|
|
US8815242B2
(en)
*
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
TWI409079B
(zh)
*
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
|
|
BR112012003066A2
(pt)
*
|
2009-08-14 |
2016-11-16 |
Roche Glycart Ag |
uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
|
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗ｃｄｃｐ１抗體
|
|
MX2012002651A
(es)
*
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
AR078651A1
(es)
*
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
PH12012501157A1
(en)
|
2009-12-22 |
2012-10-29 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
JP6042801B2
(ja)
|
2010-04-27 |
2016-12-14 |
ロシュ グリクアート アーゲー |
ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
CN103261229A
(zh)
*
|
2010-12-16 |
2013-08-21 |
罗切格利卡特公司 |
无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
HK1200850A1
(en)
|
2011-09-23 |
2015-08-14 |
罗氏格黎卡特股份公司 |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
KR102366029B1
(ko)
|
2011-09-30 |
2022-02-23 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
WO2014067642A1
(en)
|
2012-11-05 |
2014-05-08 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
MX365567B
(es)
|
2013-03-13 |
2019-06-07 |
Genentech Inc |
Formulaciones de anticuerpo.
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
EP3613433B1
(en)
|
2014-05-30 |
2022-01-05 |
Shanghai Henlius Biotech, Inc. |
Anti-epidermal growth factor receptor (egfr) antibodies
|
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
WO2016072938A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Nanyang Technological University |
Stabilized and autonomous antibody vh domain
|
|
WO2016073664A1
(en)
*
|
2014-11-05 |
2016-05-12 |
The University Of Chicago |
Methods and compositions pertaining to human cerebral cavernous malformations
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CN116196414A
(zh)
*
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
|
CN107847592B
(zh)
*
|
2015-06-24 |
2022-01-21 |
豪夫迈·罗氏有限公司 |
用于在淋巴瘤或白血病中诱导淋巴细胞增多的针对人csf-1r的抗体
|
|
CN108026172B
(zh)
|
2015-06-26 |
2022-04-29 |
赛诺菲生物技术公司 |
单克隆抗il-1racp抗体
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
|
AU2017240801A1
(en)
*
|
2016-04-01 |
2018-10-25 |
Amgen Inc. |
Chimeric receptors to FLT3 and methods of use thereof
|
|
WO2017184553A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
|
US10277886B2
(en)
|
2016-07-19 |
2019-04-30 |
Gopro, Inc. |
Mapping of spherical image data into rectangular faces for transport and decoding across networks
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
|
|
JP2020528061A
(ja)
|
2017-07-26 |
2020-09-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
|
|
WO2019036433A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
PL3765489T3
(pl)
|
2018-03-13 |
2025-02-10 |
F. Hoffmann-La Roche Ag |
Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3887386A4
(en)
*
|
2018-11-26 |
2022-11-30 |
North Carolina State University |
PEPTIDE LIGANDS FOR CAPTURE OF HOST CELL PROTEINS
|
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
|
KR20220024637A
(ko)
*
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
|
|
AU2020322031A1
(en)
|
2019-07-31 |
2022-03-10 |
The Wistar Institute Of Anatomy And Biology |
Multivalent DNA antibody constructs and use thereof
|
|
ES3064633T3
(en)
|
2019-09-12 |
2026-04-28 |
Hoffmann La Roche |
Compositions and methods of treating lupus nephritis
|
|
CR20220166A
(es)
|
2019-10-18 |
2022-06-15 |
Genentech Inc |
Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
|
|
CN111411079B
(zh)
*
|
2020-03-27 |
2025-12-12 |
北京时合生物科技有限公司 |
细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
|
|
MX2022013198A
(es)
|
2020-04-24 |
2022-11-14 |
Genentech Inc |
Metodos de uso de inmunoconjugados anti-cd79b.
|
|
EP4149547A4
(en)
|
2020-05-13 |
2024-08-14 |
Adagene AG |
Compositions and methods for treating cancer
|
|
CN116829598A
(zh)
|
2021-01-06 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
|
|
EP4454652A3
(en)
|
2021-03-15 |
2025-05-21 |
F. Hoffmann-La Roche AG |
Compositions and methods for treating lupus nephritis
|
|
EP4337266A1
(en)
|
2021-05-12 |
2024-03-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
US12054552B2
(en)
|
2022-09-21 |
2024-08-06 |
Sanofi Biotechnology |
Humanized anti-IL-1R3 antibody and methods of use
|
|
IL320029A
(en)
|
2022-11-08 |
2025-06-01 |
Genentech Inc |
Compositions and methods for treating childhood idiopathic nephrotic syndrome
|
|
TW202604943A
(zh)
|
2024-04-24 |
2026-02-01 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
|
WO2026072685A1
(en)
|
2024-09-25 |
2026-04-02 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|